Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Date: November 5, 2014
Context: This filing announces regulatory submissions for mepolizumab, an investigational monoclonal antibody, for the treatment of severe eosinophilic asthma in the USA and Europe.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory announcement regarding a specific drug candidate and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The primary material event is the submission of:
- A Biologics Licence Application (BLA) to the US FDA for patients aged 12 and older.
- A Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for adult patients.
Outlook, Management Commentary, and Risks
Management Commentary: Dave Allen, Head of Respiratory Therapy Area Unit, R&D, stated that severe asthma has serious health consequences and that mepolizumab represents a further step toward making treatment available for patients with elevated eosinophil levels whose disease remains uncontrolled.
Outlook: Regulatory filings in other countries are planned during the course of 2014 and 2015. Mepolizumab is not currently approved for use anywhere in the world.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties, including those described in the company's 2013 Annual Report on Form 20-F under "Risk factors."
Key Facts for Investor Verification
- Mepolizumab is an anti-IL5 monoclonal antibody delivered via subcutaneous injection every four weeks.
- Submissions are based on Phase III MENSA and SIRIUS studies (published September 2014) and the Phase IIb/III DREAM study (published 2012).
- The target patient population is defined by specific blood eosinophil counts (150 cells/microlitre at start or 300 cells/microlitre in the past 12 months).
- The drug is currently investigational and not approved in any jurisdiction.